Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04384380|
Recruitment Status : Completed
First Posted : May 12, 2020
Last Update Posted : August 4, 2020
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Coronavirus Infection||Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]||Not Applicable|
On December 31, 2019, an outbreak of respiratory illness later proved to be caused by a novel coronavirus, officially named Coronavirus Disease 2019 (COVID-19), was notified first in Wuhan, a city of Hubei province, People's Republic of China (PRC). COVID-19 rapidly spreads in China and to other parts of the world. Currently more than 370,000 laboratory-confirmed cases have been reported worldwide, and the case count has been rising daily, and caused a global health emergency. As of March 29, 2020, there were 298 confirmed cases in Taiwan.
This is a multi-center, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of Hydroxychloroquine Sulfate (HCQ) in adult Patients with mild to moderate coronavirus disease (COVID-19) compared to standard of care treatment (SOC). The primary endpoint for the study is to evaluate the efficacy of HCQ, with respect to the time to negatively rRT-PCR assessments from the randomization date up to 14 days. The secondary endpoint is to evaluate the efficacy of HCQ in the aspect of virological assessments and the change of clinical symptoms. In addition, the safety and tolerability of HCQ will be evaluated during treatment period in COVID-19 patients.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||33 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||The study will employ an open-label parallel design, to evaluate the efficacy and safety between hydroxychloroquine sulfate (plaquenil) and controlled standard of care treatment. The administration plan of HCQ is 400 mg bid on Day 1 and 200 mg bid for 6 days on Day 2-7. All of the enrolled subjects will receive standard of care. The comparison group will receive standard of care, i.e., supportive treatment for subjects with mild COVID-19 clinical illness.|
|Masking:||None (Open Label)|
|Official Title:||A Multi-center, Randomized, Open-label, Controlled Trial to Evaluate the Efficacy and Tolerability of Hydroxychloroquine (HCQ) in Adult Patients With Mild to Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment|
|Actual Study Start Date :||April 1, 2020|
|Actual Primary Completion Date :||May 31, 2020|
|Actual Study Completion Date :||May 31, 2020|
Experimental: HCQ in adult Patients with COVID-19
The administration plan of HCQ is 400 mg bid on Day 1 and 200 mg bid for 6 days on Day 2-7.
Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]
Hydroxychloroquine Sulfate is 400 mg bid on Day 1 and 200 mg bid for 6 days on Day 2-7.
Other Name: Plaquenil
No Intervention: standard of care treatment (SOC)
The comparison group will receive standard of care, i.e., supportive treatment for subjects with mild COVID-19 clinical illness.
- Time to negatively RT-PCR [ Time Frame: 14 days ]To evaluate the efficacy of HCQ, with respect to the time to negatively RT-PCR assessments in COVID-19 patients.
- Virologic assessment [ Time Frame: 14 days ]To evaluate the efficacy of HCQ in the aspect of virologic assessments in COVID-19 patients
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 28 days ]To evaluate the safety and tolerability of HCQ
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||20 Years to 79 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patients who had fever (central temperature ≥38°C) or acute upper respiratory symptoms and laboratory confirmation (rRT-PCR) for COVID-19, with available same type of upper respiratory tract specimens from screening evaluation to the initial testing within 4 days of initial testing
Patients have mild (no pneumonia) to moderate disease (pneumonia without respiratory distress) according to the following World Health Organization (WHO) definition of COVID-19 clinical syndromes:
- Mild (Mild illness):
Patients with uncomplicated upper respiratory tract viral infection, may have non-specific symptoms such as fever, fatigue, cough (with or without sputum production), anorexia, malaise, muscle pain, sore throat, dyspnea, nasal congestion, or headache. Rarely, patients may also present with diarrhoea, nausea and vomiting.
- Moderate (Pneumonia):
Adult with pneumonia but no signs of severe pneumonia and no need for supplemental oxygen.
- Willing and able to comply with the study procedure and sign a written informed consent
- Patients with the medical history of hypersensitivity to chloroquine, chloroquinine, or hydroxychloroquine
- Patients with retinal disease, hearing loss, severe neurological and mental illness
- Patients with pancreatitis
- Patients with severe lung, liver (alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevation more than 3 times the normal upper limit), kidney (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73m2, using the MDRD or CKD-EPI methods), brain, haematological diseases or other important systemic diseases
- Medical history of uncontrolled but clinically significant abnormal cardiac conduction abnormalities at electrocardiogram (ECG) at screening, any history or evidence of long QT syndrome or QTcF interval >450 msec for males and >470 msec for females (according to Fridericia's correction) at screening
- Known HIV infection; active hepatitis B or C without concurrent treatment (positive tests for hepatitis B [both HBsAg and HBeAg], or high titer of hepatitis C ribonucleic acid [RNA] >800,000 IU/ml)
- Uncontrolled and unstable concurrent medical condition including psychiatric disorders and alcohol/substance dependence/abuse that will jeopardize the safety of the patient, interfere with the objectives of the study, or affect the patient compliance with study requirements, as determined by the Investigator
- Patients with concomitant use of medications that alter the absorption or excretion of hydroxychloroquine
- Patients were considered to be unable to complete the study, or not suitable for the study judged by Investigators
- Pregnant or breast-feeding women
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04384380
|Taoyuan General Hospital, Ministry of Health and Welfare|
|Taoyuan City, Taiwan, 320|
|Principal Investigator:||Shu-Hsing Cheng, Dr.||Taoyuan General Hospital, Ministry of Health and Welfare|
Documents provided by Taoyuan General Hospital:
|Responsible Party:||Taoyuan General Hospital|
|Other Study ID Numbers:||
|First Posted:||May 12, 2020 Key Record Dates|
|Last Update Posted:||August 4, 2020|
|Last Verified:||March 2020|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Plan Description:||The study outcome will be shared with the experts and persons interested in this field.|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Respiratory Tract Infections
RNA Virus Infections
Respiratory Tract Diseases
Molecular Mechanisms of Pharmacological Action